| |
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs.
|
|
Today’s Big NewsJan 18, 2024 |
|
This whitepaper explains how Resilience utilizes a Stage-Gate approach to technology transfer and biomanufacturing. Built on proven methods used across industries, the Stage-Gate approach mitigates risk while shortening cycle times throughout the project lifecycle.
|
|
| By Angus Liu Bayer is launching a sweeping business overhaul that will “come at the expense of many managerial employees,” as the German conglomerate sees “no viable alternative.” |
|
|
|
By Nick Paul Taylor BridgeBio Pharma is building a war chest for its showdown with Pfizer. Facing a deep-pocketed rival, the biotech has struck a set of financing deals worth up to $1.25 billion to support an anticipated launch and a schedule of phase 3 readouts for other assets. |
By Andrea Park To comply with the now-reinstated import ban, newly sold Series 9 and Ultra 2 Apple Watch models in the U.S. will no longer offer the blood oxygen measurement feature. |
By Fraiser Kansteiner While the first-mover advantage is often critical in the realm of drug launches, Eli Lilly is often happy to split the pie with its peers. That’s proven true in obesity, where the company recently introduced its dual-action GIP/GLP-1 agonist Zepbound against Novo Nordisk’s Wegovy. The situation is shaping up to be much the same in Alzheimer’s disease. |
By Max Bayer Surrozen has halted the development of its clinical-stage IBD med, due in part to trouble with dose safety. The company says that "several" patients at higher dose levels experienced asymptomatic increases in liver enzymes. |
By Conor Hale Abbott announced it has begun conducting the first human procedures using its new Volt system, through a clinical study of more than 30 patients in Australia. |
By Kevin Dunleavy It took 17 years for Sun Pharmaceutical and Taro Pharmaceutical to finally tie the knot. On Thursday, the companies revealed their long-awaited merger, with Sun of Mumbai, India, agreeing to purchase outstanding shares in the Israeli drugmaker for $43 each. The deal nets out to $348 million for a 48% premium on Taro's share price of $29. |
By Gabrielle Masson Mirae Asset Capital Life Science has exited stealth mode with $50 million ready to go for certain U.S. biotechs. |
By Andrea Park The FDA noted in the safety alert that Exactech has “declined to initiate a voluntary recall” for the affected Equinoxe shoulder implants, but added that it is still working with the company to review information about the devices’ safety and effectiveness. |
By Zoey Becker In the latest update in Satsuma's migraine nasal spray saga, the FDA flagged issues with chemistry, manufacturing and controls in its complete response letter. |
By James Waldron CG Oncology is hoping to raise $209 million from its upcoming IPO, blazing a trail to the public markets that seems to be enticing more biotechs in the first month of the year. |
Fierce podcastsDon’t miss an episode |
| | A growing number of companies are introducing diverse voices to their virtual assistants or speech synthesis systems: Apple’s Siri, Amazon’s Polly, Meta’s Voicebox. But what about diversity of voices in healthcare, where the stakes are higher? |
|
|---|
|
|
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
